Readoutin 14d
Janssen Research & Development, LLC — Ibrutinib
Phase 3 primary completion: A Long-term Extension Study of PCI-32765 (Ibrutinib).
- Date
- Dec 2026
- Type
- Readout
- Indication
- Chronic Lymphocytic Leukemia
Readoutin 14d
Phase 3 primary completion: A Long-term Extension Study of PCI-32765 (Ibrutinib).
The weekly brief is free. Pro adds reminders 7 days and 1 day before.